Abstract
Objective:
Hemodialysis can significantly prolong the survival of uremia patients, but uremia and long-term hemodialysis can also cause complications. This study aimed to compare the clinical efficacy between the menostat mesylate and sodium citrate as anticoagulants in patients receiving CRRT.
Methods:
The clinical data of 80 patients with uremic cerebral hemorrhage in our hospital from January 2020 to October 2022 were collected and randomly divided into observation (nelostat anticoagulation, n = 40) and control (citrate and sodium anticoagulation, n = 40) groups. Physiological parameters, CRRT filter life, coagulation function index, activated whole blood coagulation time (ACT), anticoagulation efficiency rate, and incidence of adverse reactions were compared between the two groups.
Results:
The physiological index, coagulation function index, ACT value, and anticoagulation efficiency were higher in the observation group than in the control group (p < 0.05). The observation group also demonstrated a longer CRRT filter life and lower incidence of adverse reactions than those in the control group (both p < 0.5).
Conclusion:
Naphlimostat mesylate demonstrated a good anticoagulant effect and was safe for use in CRRT.
Get full access to this article
View all access options for this article.